The role of cocrystals in pharmaceutical science

被引:626
作者
Shan, Ning [1 ]
Zaworotko, Michael J. [2 ]
机构
[1] Thar Pharmaceut Inc, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Chem, Tampa, FL 33620 USA
关键词
D O I
10.1016/j.drudis.2008.03.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmaceutical cocrystals, a subset of a long known but little-studied class of compounds, represent an emerging class of crystal forms in the context of pharmaceutical science. They are attractive to pharmaceutical scientists because they can significantly diversify the number of crystal forms that exist for a particular active pharmaceutical ingredient (API), and they can lead to improvements in physical properties of clinical relevance. In this article we address pharmaceutical cocrystals from the perspective of design (crystal engineering) and present a series of case studies that demonstrate how they can enhance the solubility, bioavailability, and/or stability of API crystal forms.
引用
收藏
页码:440 / 446
页数:7
相关论文
共 61 条
[1]   Building co-crystals with molecular sense and supramolecular sensibility [J].
Aakeröy, CB ;
Salmon, DJ .
CRYSTENGCOMM, 2005, 7 :439-448
[2]  
Allen F.H., 1993, CHEM AUTOMAT NEWS, V8, P31
[3]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[4]   Structure of organic molecular compounds [J].
Anderson, JS .
NATURE, 1937, 140 :583-584
[5]  
[Anonymous], 1995, SUPRAMOLECULAR CHEM
[6]   Amide-N-oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine N-oxides [J].
Babu, N. Jagadeesh ;
Reddy, L. Sreenivas ;
Nangia, Ashwini .
MOLECULAR PHARMACEUTICS, 2007, 4 (03) :417-434
[7]   Hierarchy of supramolecular synthons:: Persistent hydroxyl•••pyridine hydrogen bonds in cocrystals that contain a cyano acceptor [J].
Bis, Joanna A. ;
Vishweshwar, Peddy ;
Weyna, David ;
Zaworotko, Michael J. .
MOLECULAR PHARMACEUTICS, 2007, 4 (03) :401-416
[8]   Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates [J].
Blagden, N. ;
de Matas, M. ;
Gavan, P. T. ;
York, P. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) :617-630
[9]   What is a co-crystal? [J].
Bond, Andrew D. .
CRYSTENGCOMM, 2007, 9 (09) :833-834
[10]   Making crystals from crystals: a green route to crystal engineering and polymorphism [J].
Braga, D ;
Grepioni, F .
CHEMICAL COMMUNICATIONS, 2005, (29) :3635-3645